The present disclosure relates to the field of combination therapy for treatment of hematological malignancy selected from myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The disclosure provides a combination therapy comprising plant based compounds and hypomethylating agent (HMA). Particularly, the disclosure provides a combination of: a) a therapeutically effective amount of a combination comprising sulforaphane, resveratrol and curcumin; and b) a therapeutically effective amount of HMA selected from azacitidine (AZA), decitabine (DEC) and a combination thereof, for treating MDS or AML. Said combination provides an enhanced/synergistic effect in the treatment of MDS or AML along with decreasing or overcoming resistance to HMA (azacitidine or decitabine). Methods for decreasing or overcoming resistance to HMA (azacitidine or decitabine), corresponding use of the above described combination and a kit comprising said combination are also provided.

The present disclosure relates to the field of combination therapy for treatment of hematological malignancy selected from myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The disclosure provides a combination therapy comprising plant based compounds and hypomethylating agent (HMA). Particularly, the disclosure provides a combination of: a) a therapeutically effective amount of a combination comprising sulforaphane, resveratrol and curcumin; and b) a therapeutically effective amount of HMA selected from azacitidine (AZA), decitabine (DEC) and a combination thereof, for treating MDS or AML. Said combination provides an enhanced/synergistic effect in the treatment of MDS or AML along with decreasing or overcoming resistance to HMA (azacitidine or decitabine). Methods for decreasing or overcoming resistance to HMA (azacitidine or decitabine), corresponding use of the above described combination and a kit comprising said combination are also provided.

Disclosed are novel mechanisms of action of ivermectin therapy as related to treatment of COVID-19 and means of augmenting therapeutic activities by co-administration with one or more of the following: pterostilbene, thymoquinone, epigallocatechin-3-gallate, and sulforaphane. In one embodiment the invention provides enhanced reduction of inflammation induced pulmonary leakage without augmenting immune suppressive mechanisms.

Disclosed are novel mechanisms of action of ivermectin therapy as related to treatment of COVID-19 and means of augmenting therapeutic activities by co-administration with one or more of the following: pterostilbene, thymoquinone, epigallocatechin-3-gallate, and sulforaphane. In one embodiment the invention provides enhanced reduction of inflammation induced pulmonary leakage without augmenting immune suppressive mechanisms.

Disclosed are novel mechanisms of action of ivermectin therapy as related to treatment of COVID-19 and means of augmenting therapeutic activities by co-administration with one or more of the following: pterostilbene, thymoquinone, epigallocatechin-3-gallate, and sulforaphane. In one embodiment the invention provides enhanced reduction of inflammation induced pulmonary leakage without augmenting immune suppressive mechanisms.

The present invention discloses means and methods for enhancing cannabinoids efficacy. The invention relates to invigorating performance of cannabinoid by means of combining compounds to prime the binding cannabinoid receptors and promoting demethylation processes. Specifically, the present invention discloses a plant-based composition configured to enhance a physiological effect of a cannabis-derived compound, wherein said composition comprises a synergistic combination of the cannabis-derived compound, at least one portion of at least one plant comprising a methylating/demethylating active agent, and at least one portion of at least one enhancer plant.

The present invention discloses means and methods for enhancing cannabinoids efficacy. The invention relates to invigorating performance of cannabinoid by means of combining compounds to prime the binding cannabinoid receptors and promoting demethylation processes. Specifically, the present invention discloses a plant-based composition configured to enhance a physiological effect of a cannabis-derived compound, wherein said composition comprises a synergistic combination of the cannabis-derived compound, at least one portion of at least one plant comprising a methylating/demethylating active agent, and at least one portion of at least one enhancer plant.

The present invention discloses means and methods for enhancing cannabinoids efficacy. The invention relates to invigorating performance of cannabinoid by means of combining compounds to prime the binding cannabinoid receptors and promoting demethylation processes. Specifically, the present invention discloses a plant-based composition configured to enhance a physiological effect of a cannabis-derived compound, wherein said composition comprises a synergistic combination of the cannabis-derived compound, at least one portion of at least one plant comprising a methylating/demethylating active agent, and at least one portion of at least one enhancer plant.

A healing composition includes about 80 wt. % olive oil; about 15 wt. % kosher salt; and about 5 wt. % liquid rosemary. The healing composition is made by providing olive oil in a container; adding kosher salt to the container; adding liquid rosemary to the container; and mixing the olive oil, kosher salt, and liquid rosemary.

A healing composition includes about 80 wt. % olive oil; about 15 wt. % kosher salt; and about 5 wt. % liquid rosemary. The healing composition is made by providing olive oil in a container; adding kosher salt to the container; adding liquid rosemary to the container; and mixing the olive oil, kosher salt, and liquid rosemary.